Lipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.com

Posted by Casey Walker on May 3rd, 2025

Investment analysts at StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN – Get Free Report) in a note issued to investors on Thursday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Performance

NASDAQ LPCN opened at $3.41 on Thursday. Lipocine has a twelve month low of $2.75 and a twelve month high of $11.79. The stock has a market cap of $18.24 million, a PE ratio of -4.49 and a beta of 1.51. The firm has a 50-day simple moving average of $3.22 and a 200 day simple moving average of $4.22.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Lipocine stock. Geode Capital Management LLC grew its holdings in Lipocine Inc. (NASDAQ:LPCN – Free Report) by 6.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 57,464 shares of the specialty pharmaceutical company’s stock after buying an additional 3,248 shares during the quarter. Geode Capital Management LLC owned 1.07% of Lipocine worth $280,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

(Get Free Report)

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.